Antithyroid drugs.
Cooper
David S
DS
Division of Endocrinology, Sinai Hospital of Baltimore, the Johns Hopkins University School of Medicine, Baltimore 21215, USA. dcooper@lifebridgehealth.org
D000380:Agranulocytosis / Q000139:chemically induced; D000465:Algorithms; D013956:Antithyroid Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D005260:Female; D006111:Graves Disease / Q000188:drug therapy*; D006801:Humans; D006980:Hyperthyroidism / Q000188:drug therapy; D008713:Methimazole / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy; D011441:Propylthiouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D013961:Thyroid Gland / Q000187:drug effects; D013971:Thyrotoxicosis / Q000188:drug therapy; D013974:Thyroxine / Q000096:biosynthesis; D014284:Triiodothyronine / Q000096:biosynthesis
D013956:Antithyroid Agents; D014284:Triiodothyronine; D008713:Methimazole; D011441:Propylthiouracil; D013974:Thyroxine